1 minute reading time (230 words)

You’re Invited! Special Event: Diagnosis and Evidence-Based Management of T-Cell Lymphoma

i3 Health would like to cordially invite you to our upcoming event, Diagnosis and Evidence-Based Management of T-Cell Lymphoma, a live CME/NCPD-approved webinar.

Due to high demand, we are pleased to offer two dates and times for this expert-led discussion: Monday, June 13, 2022, at 3:00 PM EDT, and Friday, June 17, 2022, at 12:00 PM EDT.

T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging.

To tackle the knowledge gaps surrounding diagnosis and management of TCL, Aaron Goodman, MD, Hematologist/Medical Oncologist and Associate Professor of Medicine at the University of San Diego Health, will be guiding us through a dynamic discussion encompassing the latest insights on the following:

  • Diagnosing T-cell lymphoma, including subtypes
  • Efficacy and safety data for novel agents
  • Tailoring treatment plans to individual patients
  • Incorporating novel agents into treatment strategies
  • Optimizing tolerability of treatment
  • Managing treatment-related adverse events
  • Applying strategies to manage symptoms and optimize a patient's quality of life
  • And much more!

Don't miss the chance to enhance your clinical practice and earn free CME, NCPD, MOC, and ILNA! Reserve your seat today at i3health.com/tcl-webinar.

We look forward to seeing you there!


Related Posts

Copyright © 2022 Oncology Data Advisor. All rights reserved.